New Study to Test Liver Dialysis for Treatment of Acetaminophen Overdose.
SAN DIEGO--(BW HealthWire)--May 21, 2001
HemoTherapies Inc. and Rocky Mountain Poison and Drug Control
Enter Collaboration to Further Define Use of the
HemoTherapies Inc. and Rocky Mountain Poison and Drug Center (RMPDC) today announced their collaboration to further study the HemoTherapies Unit(TM) for Liver Dialysis as a treatment for acetaminophen or severe drug overdose cases.
The objective of the study is to determine the appropriate point to use Liver Dialysis therapy in the treatment of patients with severe acetaminophen overdose.
"We have already seen the HemoTherapies Unit save lives and eliminate the need for liver transplants with many drug overdose patients," said David Mazepink, President & CEO of HemoTherapies. "This study will allow us to create a standard of care for acetaminophen overdose patients at risk of liver failure. It will also enable us to continue to reduce the number of deaths or transplants associated with acetaminophen overdose."
Liver Dialysis is a therapeutic option available through the HemoTherapies Unit that effectively clears toxins from the bloodstream, diminishing stress on the liver and enabling physicians to stabilize their patients. The Unit is the only liver assist technology with FDA clearance for the treatment of patients suffering from drug overdose and acute hepatic encephalopathy due to decompensating liver disease.
"When used properly, acetaminophen is a very safe and effective drug, however, when improperly used it can cause liver toxicity," Dr. Richard Dart, Director of the Rocky Mountain Poison and Drug Control Center said. "There are few treatment options available for acetaminophen poisoning. NAC (N-acetylcysteine) is the standard therapy and is very effective if used early. However, NAC alone is not sufficient therapy for some patients. Evidence to date about Liver Dialysis is promising and suggests that it has the potential to successfully treat these patients. We look forward to further studying this innovative therapy."
The study will be a multi-center study and is scheduled to begin in the second half of 2001. Currently RMPDC and HemoTherapies are developing a protocol for collecting retrospective data regarding the use of the HemoTherapies Unit for treating patients with acetaminophen poisoning.
"The HemoTherapies Unit may offer a much needed treatment option for severe acetaminophen overdose patients who are at risk for developing liver failure," stated Dr. Barry Rumack, developer of the current drug overdose diagnostic standards. "By defining appropriate routine use for the Unit, we will be able to help more patients and successfully treat a number of the liver failure cases associated with drug overdose."
HemoTherapies Inc. is dedicated to applying technology and services for the benefit of patients with liver disease. HemoTherapies markets and distributes advanced liver care technology, services and programs for patients suffering from liver disease or liver impairment due to hepatitis, cirrhosis, overdose, drug toxicity, aggressive drug therapies or other causes, for use in hospitals nationwide. The HemoTherapies Unit for Liver Dialysis is the only liver assist technology with FDA clearance for the treatment of patients suffering from acute hepatic encephalopathy due to decompensating liver disease and drug overdose.
For additional information about liver dialysis visit the HemoTherapies Web site at www.hemotherapies.com.
About Rocky Mountain Poison and Drug Center
The Rocky Mountain Poison and Drug Center (RMPDC) is a medical information center that specializes in poison exposure management, consulting and reporting. Located in Denver, the RMPDC has provided 24-hour poison emergency service for nearly half a century. We serve the residents of Colorado, Montana, Idaho, and southern Nevada as their poison center as well as many chemical and pharmaceutical manufacturers throughout the United States. This year RMPDC will serve over 140,000 callers. RMPDC is one of 45 centers certified by the American Association of Poison Control Centers and is a division of the Denver Health and Hospitals Authority.
The statements made in this press release contain certain forward-looking statements that involve a number of risks and uncertainties including, but not limited to, current product development, demand and market acceptance risks, the impact of competitive products and pricing, regulatory approval and future product development. Actual events or results may differ from HemoTherapies Inc.'s expectations. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
For additional information about RMPDC visit their Web site at www.rmpdc.org.
|Printer friendly Cite/link Email Feedback|
|Date:||May 21, 2001|
|Previous Article:||Motorola and Green Hills Software Announce Planned Technology Alliance.|
|Next Article:||Gartner Dataquest Says Worldwide Storage Management Software Market to Reach $17 Billion by 2005.|